{
  "source": "PA-Med-Nec-Lucemyra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2156-7\nProgram Prior Authorization/Medical Necessity\nMedication Lucemyra® (lofexidine)\nP&T Approval Date 11/2018, 11/2019, 1/2021, 2/2022, 2/2023, 2/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nLucemyra is a central alpha-2 adrenergic agonist indicated for mitigation of opioid\nwithdrawal symptoms to facilitate abrupt opioid discontinuation in adults.\n2. Coverage Criteriaa:\nA. Lucemyra will be approved based on the following criteria:\n1. All of the following:\na. For symptoms of abrupt opioid withdrawal. b\n-AND-\nb. Opioids have been discontinued. b\n-AND-\nc. One of the following:\n(1) History of failure, contraindication, or intolerance to clonidine.\n-OR-\n(2) Lucemyra was initiated in the inpatient setting.\nAuthorization will be issued for 14 days of therapy. If Lucemyra was initiated in\nthe inpatient setting, the total course of therapy should not exceed 14 days.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb Plans sitused in Nevada are not subject to clinical criteria. Only step therapy may be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2025 UnitedHealthcare Services Inc.\n1\n• Supply limits may also apply.\n4. References:\n1. Lucemyra [prescribing information]. Louisville, KY: WorldMeds, LLC; October 2023.\nGowing L, Farrell M, Ali R, White J. Alpha2-adrenergic agonists for the management of\nopioid withdrawal. Cochrane Database of Systemic Reviews 2016, Issue 5.\nProgram Prior Authorization/Medical Necessity – Lucemyra\nChange Control\nDate Change\n11/2018",
    "ergic agonists for the management of\nopioid withdrawal. Cochrane Database of Systemic Reviews 2016, Issue 5.\nProgram Prior Authorization/Medical Necessity – Lucemyra\nChange Control\nDate Change\n11/2018 New program.\n11/2019 Annual review. No changes to criteria.\n1/2021 Annual review. No changes to criteria.\n2/2022 Annual review. Updated references.\n2/2023 Annual review. No changes.\n2/2024 Annual review. Nevada footnote added. Updated references.\n4/2025 Annual review with no changes.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}